Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III self-controlled study of oral aminolevulinic acid hydrochloride granules with cystoscopic PDD fluorescence imaging versus white-light cystoscopy for detection of non-muscle-invasive bladder cancer
CTR20244882Phase 3Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 5-aminolevulinic acid in non-muscle-invasive bladder cancer (NMIBC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Mar 2025; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20244882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244882.